Trials / Unknown
UnknownNCT05134298
Pharmacokinetics of Piperacillin and Meropenem in ICU Patients
First Dose Pharmacokinetics for Piperacillin and Meropenem in ICU Patients
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (estimated)
- Sponsor
- Karolinska University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to characterize the pharmacokinetics of meropenem and piperacillin in ICU-patients at the time of the first dose administration and to contrast that with the same measurements obtained in the same patient 2-3 days later during the course of ICU treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Piperacillin/tazobactam, Meropenem | This is an observational study exploring the antibiotic plasma concentration profiles in ICU paitents after the first drug administration. |
Timeline
- Start date
- 2019-11-01
- Primary completion
- 2022-12-31
- Completion
- 2023-12-31
- First posted
- 2021-11-24
- Last updated
- 2021-11-24
Locations
1 site across 1 country: Sweden
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05134298. Inclusion in this directory is not an endorsement.